ZTS Q2 2024 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.4B+8.3% YoY

Gross Profit

$1.7B70.2% margin

Operating Income

$906M38.4% margin

Net Income

$624M26.4% margin

EPS (Diluted)

$1.37

QoQ Revenue Growth

+7.8%

Cash Flow

Operating Cash Flow

$502M

Free Cash Flow

$370M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$14.2B

Total Liabilities

$9.2B

Stockholders' Equity

$5.0B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.2B	+8.3%
Gross Profit	$1.7B	$1.5B	+7.9%
Operating Income	$906M	$834M	+8.6%
Net Income	$624M	$671M	-7.0%

Revenue Segments

Dogs and Cats

$1.6B68%

Cattle

$350M15%

Poultry

$132M6%

Swine

$130M6%

Horses

$68M3%

Fish

$62M3%

Geographic Segments

United States Segment

$1.3B56%

International Segment

$1.0B44%